Finance

Lists
EVH:NYSE
Evolent Health Inc
USD 3,54
+0,57%
(+0,020) 1D
30 Sep., 13:14:18 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVH...
Open
USD 3,53
High
USD 3,58
Low
USD 3,41
Mkt. cap
400,80 m
Avg. vol.
2,47 m
Volume
709,98 k
52-wk high
USD 8,59
52-wk low
USD 2,10
EPS
-USD 4,57
Beta
0,84
Shares outstanding
113,06 m
No. of employees
4 k
Open
USD 3,53
High
USD 3,58
Low
USD 3,41
Mkt. cap
400,80 m
Avg. vol.
2,47 m
Volume
709,98 k
52-wk high
USD 8,59
52-wk low
USD 2,10
EPS
-USD 4,57
Beta
0,84
Shares outstanding
113,06 m
No. of employees
4 k
About Evolent Health Inc
CEO-
Employees4,2 k
Founded2011
Headquarters-
SectorHealth care
Websiteevolent.com
Analyst ratings
Based on 12 analysts giving stock ratings to EVH in the past 3 months
Strong buy
Buy
9
Hold
3
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for EVH in the last 3 months.
Highest
Current USD 3,54
USD 8,00 (+125,67%)
Average
USD 5,80 (+63,61%)
Lowest
USD 3,00 (-15,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Stansel
J.P. Morgan
Buy
Reiterated
USD 6,00
+69,3%
08/18/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
USD 6,00
+69,3%
08/17/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
USD 6,00
+69,3%
08/12/2026
Daniel Grosslight
Citi
Buy
Upgraded
USD 6,00
+69,3%
08/11/2026
Richard Close
Canaccord Genuity
Buy
Maintained
USD 6,00
+69,3%
08/10/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
08/10/2026
Michael Wiederhorn
Oppenheimer
Buy
Reiterated
USD 6,00
+69,3%
08/07/2026
Sean Dodge
BMO Capital
Buy
Maintained
USD 6,00
+69,3%
08/06/2026
Ryan Halsted
RBC Capital
Hold
Maintained
USD 3,00
-15,4%
08/06/2026
Matthew Shea
Needham
Buy
Reiterated
USD 5,00
+41%
08/06/2026
Ryan Daniels
William Blair
Buy
Reiterated
-
-
08/06/2026
David Larsen
BTIG
Buy
Reiterated
USD 8,00
+125,7%
07/16/2026
Kevin Caliendo
UBS
Buy
Reiterated
USD 5,00
+41%
05/08/2026
Jeffrey Garro
Stephens
Buy
Maintained
USD 7,00
+97,5%
02/25/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 0,02 / -USD 0,02
+229,87%beat
Revenue / Est. (USD)
652,52 m / 599,79 m
+8,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
479,53 m
468,72 m
496,25 m
652,52 m
Cost of goods sold
379,76 m
371,47 m
412,47 m
571,68 m
Cost of revenue
379,76 m
371,47 m
412,47 m
571,68 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
75,50 m
61,86 m
72,36 m
67,99 m
Operating expense
99,12 m
106,89 m
93,91 m
89,55 m
Total operating expenses
478,88 m
478,36 m
506,38 m
661,24 m
Operating income
658,00 k
-9,64 m
-10,14 m
-8,72 m
Other non operating income
80,00 k
-552,00 k
742,00 k
109,00 k
EBT including unusual items
-19,96 m
-430,81 m
-25,72 m
-25,65 m
EBT excluding unusual items
-14,62 m
-28,30 m
-25,26 m
-24,80 m
Income tax expense
906,00 k
-1,68 m
910,00 k
2,72 m
Effective tax rate
-4,54%
0,39%
-3,54%
-10,59%
Other operating expenses
-
-
-
-
Net income
-20,86 m
-429,13 m
-26,63 m
-28,36 m
Net profit margin
-4,35%
-91,55%
-5,37%
-4,35%
Earnings per share
0,05
-
-0,02
0,02
Interest and investment income
964,00 k
868,00 k
1,01 m
703,00 k
Interest expense
-16,48 m
-19,01 m
-16,87 m
-16,86 m
Net interest expenses
-15,51 m
-18,14 m
-15,85 m
-16,16 m
Depreciation and amortization charges
23,62 m
45,04 m
21,56 m
21,57 m
EBITDA
18,67 m
29,70 m
5,62 m
7,05 m
Gain or loss from assets sale
-
-14,87 m
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme